Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?

Scott M. Dehm, Bruce Montgomery, Stephen R. Plymate

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.

Original languageEnglish (US)
Pages (from-to)1696-1698
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number6
DOIs
StatePublished - 2019

Bibliographical note

Funding Information:
This work was supported by NCI RO1CA174777 (to S.M. Dehm), Prostate Cancer Foundation (to S.M. Dehm, B. Montgomery, and S.R. Plymate), P50

Funding Information:
This work was supported by NCI RO1CA174777 (to S.M. Dehm), Prostate Cancer Foundation (to S.M. Dehm, B. Montgomery, and S.R. Plymate), P50 CA097186 (to B. Montgomery and S.R. Plymate), and W81XWH-14-2-0183, W81XWH-15-1-0430, the Veterans Affairs Research Program, and NCI P01CA163227 (all to S.R. Plymate)

Publisher Copyright:
© 2018 American Association for Cancer Research.

Keywords

  • Humans
  • Male
  • Neoplastic Cells, Circulating
  • Prostatic Neoplasms, Castration-Resistant
  • RNA, Messenger
  • Receptors, Androgen
  • Taxoids

PubMed: MeSH publication types

  • Comment
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?'. Together they form a unique fingerprint.

Cite this